UK markets close in 4 hours 42 minutes

10x Genomics, Inc. (0A88.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
36.33-0.38 (-1.04%)
As of 06:36PM GMT. Market open.
Full screen
Previous close36.71
Open0.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range0.00 - 0.00
52-week range
Volume0
Avg. volume574
Market capN/A
Beta (5Y monthly)1.92
PE ratio (TTM)N/A
EPS (TTM)-0.80
Earnings date01 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay

    10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product. This assay enables researchers to measure the whole transcriptome from FFPE tissue sections at single cell-scale resolution.

  • PR Newswire

    10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

    10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications. These new products expand the breadth of the Xenium single cell spatial analysis menu.

  • PR Newswire

    10x Genomics Begins Commercial Shipments of Chromium GEM-X Products

    10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3. GEM-X is the next generation of the company's leading single cell technology architecture and is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized re